Intellia Therapeutics (NTLA) Shares Outstanding (Weighted Average) (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Shares Outstanding (Weighted Average) data on file, last reported at $118.5 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $118.5 million, up 14.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $118.5 million (up 14.48% YoY), and the FY2025 annual result was $108.4 million, up 9.64% from the prior year.
• Shares Outstanding (Weighted Average) improved to $118.5 million in Q1 2026 per NTLA's latest filing, from $108.4 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $118.5 million in Q1 2026 and troughed at $74.8 million in Q1 2022.
• A 5-year average of $93.4 million and a median of $95.5 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) advanced 17.42% in 2023, then increased 4.79% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $77.0 million in 2022, then rose by 15.33% to $88.8 million in 2023, then grew by 11.35% to $98.8 million in 2024, then gained by 9.64% to $108.4 million in 2025, then increased by 9.33% to $118.5 million in 2026.
• Business Quant data shows NTLA's Shares Outstanding (Weighted Average) at $118.5 million in Q1 2026, $108.4 million in Q4 2025, and $105.8 million in Q3 2025.